GMA202

GMA202 is an M-Body composed of an anti-ETa monoclonal antibody and an anti-CD3 antibody fragment, simultaneously targets ETa and CD3. GMA202 pair-matches the activated T cells with ETa overexpressing ovarian cancer cells and achieves a unique and precise immunotherapy.

To meet the urgent clinical needs, GMA202 is an orphan drug specifically for the ovarian cancer patients with high ETa expression in tumor. Currently, GMA202 is in IND enabling stage.